Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
179
resultados
Última actualización
02/11/2026 [08:44:00]
Resultados 175 a 179 de 179
Resumen de: WO2026179772A1
A blood glucose assessment method, a user interface and a related apparatus. The blood glucose assessment method can acquire a PPG signal of a user, and then display a blood glucose result of the user obtained by assessment on the basis of the PPG signal, the blood glucose result indicating the stage at which the user falls in the progression from normal blood glucose to diabetes. The method takes into account that there is still a stage of development before normal blood glucose is converted into diabetes, thereby achieving more refined assessment of the blood glucose of users, so that the users achieve more refined self-management of blood glucose.
Resumen de: US20260258368A1
0000 Methods are provided for in vitro selection of metabolic selection of metabolically selectable mammalian cells that don't require exogenous glucose and glutamine in culture. Such cells may be glycogen-storing mammalian cells, including without limitation hepatocytes. Metabolic selection provides an approach to rapidly kill non-selectable cells by withholding specific nutrients from the culture medium.
Resumen de: MX2026008374A
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Nº publicación: US20260257014A1 03/09/2026
Solicitante:
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
Resumen de: US20260257014A1
Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.
BOPI
Sede Electrónica
